Precipio, Inc. PRPO
18.62 USD -0.45 (-2.33%)
As ofNov 18, 2026, 3:00 PM EST
18.46 Day range 20.20
17.79 52-week range 33.63
- YTD
- -18.99%
- 1 year
- -20.38%
- Market cap
- 33.61M
- Revenue (ttm)
- 16.72M
- Profit margin
- -22.90%
- EPS (ttm)
- -0.59
- Shares out
- 1.48M
- Forward P/E
- 13.34
- YTD return
- -18.99%
- 1-year return
- -20.38%
- Volume
- 30.35K
- Avg volume
- 86.19K
- Open
- 19.31
- Previous close
- 19.06
- Day's range
- 18.46 – 20.20
- 52-week range
- 17.79 – 33.63
- Beta
- 1.42
- 50-day average
- 6.13
5D -3.93 (-17.01%)
Key statistics
- 200-day average
- 5.98
- Enterprise value
- 9.10M
- Price / sales
- 0.46
- Price / book
- 0.51
- Revenue growth
- 25.70%
- Free cash flow
- -894.75K
- Total cash
- 1.28M
- Total debt
- 1.17M
- Return on equity
- -29.22%
- Short % of float
- 0.35%
Fundamental scorecard
10 of 25 checks passed on PRPO’s reported financials
10of 25 checks passed
- Value 2 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
PRPO Revenue — quarterly 7.33M
PRPO Net income — quarterly -8.00K
PRPO EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | 0.00 | -0.42 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.83 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -1.46 | — | — |
| Mar 29, 2024 | Dec 1, 2023 | 0.00 | -0.41 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -1.04 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -1.80 | — | — |
About Precipio, Inc.
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- precipiodx.com
News
Your note
Sign in to keep a note on PRPO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDREWS RONALD ASBURY | Director | Stock Award(Grant) | Oct 14, 2024 | 11,128 |
| COHEN DAVID SETH | Director | Stock Award(Grant) | Oct 14, 2024 | 47,560 |
| COSSMAN JEFFREY M.D. | Director | Stock Award(Grant) | Oct 14, 2024 | 12,312 |
| DANIELI ILAN | Chief Executive Officer | Purchase | Jan 2, 2023 | 57,046 |
| FISHER DOUGLAS CARL M.D. | Director | Stock Award(Grant) | Oct 26, 2023 | 5,572 |
| LAPORTE KATHLEEN D | Director | Stock Award(Grant) | Apr 14, 2024 | 10,071 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 1.95% | 28,912 | 150.38K | Sep 29, 2024 |
| Vanguard Group Inc | 1.19% | 17,645 | 91.78K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.98% | 14,458 | 75.20K | Sep 29, 2024 |
| Wells Fargo & Company | 0.04% | 550 | 2.86K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.04% | 611 | 3.18K | Sep 29, 2024 |
| Citigroup Inc. | 0.03% | 470 | 2.44K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.19% | 17,645 | 91.78K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 7,154 | 37.21K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.21% | 3,097 | 16.11K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 1,879 | 9.77K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 1,752 | 9.11K | Oct 30, 2024 |
